Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 21

Sort by

Sort Order Select

Journal Articles

Ibrutinib Plus Venetoclax in Patients With Relapsed/Refractory Mantle Cell Lymphoma: Results From the Safety Run-In Period of the Phase 3 Sympatico Study

Constantine S. Tam, MD, Radhakrishnan Ramchandren, MD, Robert Chen, MD, Lionel Karlin, MD, Geoffrey Chong, MD, Wojciech Jurczak, MD PhD, Ka Lung Wu, MD PhD, Mark Bishton, MBChB, MRCP, FRCPath, PhD, Graham P. Collins, MD DPhil, Paul Eliadis, MBBS, FRACP, FRCPA, Frédéric Peyrade, MD, Edith Szafer-Glusman, PhD, Yihua Lee, PhD, Karl Eckert, BA, Jutta K. Neuenburg, MD PhD, Michael Wang, MD

Blood (2020) 136 (Supplement 1): 39–41.

https://doi.org/10.1182/blood-2020-134392

Published: 2020

Journal Articles

Consolidation with Nivolumab and Brentuximab Vedotin after Autologous Hematopoietic Cell Transplantation in Patients with High-Risk Hodgkin Lymphoma

Blood (2020) 136 (Supplement 1): 19–20.

https://doi.org/10.1182/blood-2020-136384

Published: 2020

Journal Articles

Phase 1/2 Study of AUTO3 the First Bicistronic Chimeric Antigen Receptor (CAR) Targeting CD19 and CD22 Followed By an Anti-PD1 in Patients with Relapsed/Refractory (r/r) Diffuse Large B Cell Lymphoma (DLBCL): Results of Cohort 1 and 2 of the Alexander Study

Kirit M. Ardeshna, MBBChir, Maria A V Marzolini, Jane Norman, MD, Muhammad Al-Hajj, Simon Thomas, PhD, Jim Faulkner, Ekaterini Kotsopoulou, Martin Pule, MD, Vijay G R Peddareddigari, Nushmia Z Khokhar, Maud Jonnaert, PhD, Robert Chen, MD, Wendy Osborne, MD

Blood (2019) 134 (Supplement_1): 246.

https://doi.org/10.1182/blood-2019-122724

Published: 2019

Journal Articles

Ibrutinib Therapy in Patients with Relapsed/Refractory Marginal Zone Lymphoma: Analysis By Prior Rituximab Treatment and Baseline Mutations

Blood (2017) 130 (Supplement 1): 3026.

https://doi.org/10.1182/blood.V130.Suppl_1.3026.3026

Published: 2017

Journal Articles

Interim Analysis of a Phase 1 Study of the Antibody-Drug Conjugate SGN-CD19A in Relapsed or Refractory B-Lineage Acute Leukemia and Highly Aggressive Lymphoma

Amir T Fathi, Robert Chen, MD, Tanya M. Trippett, Maureen M. O'Brien, MD, Daniel J DeAngelo, Bijal D. Shah, MD, Todd M. Cooper, DO, James M. Foran, MD, Gregory A. Hale, MD, Joseph Pressey, MD, Lewis B. Silverman, Raoul Tibes, MD, Stella Kim, MD, Tina M. Albertson, MD PhD, Larissa Sandalic, MS, Baiteng Zhao, PhD, Uma Borate, MD

Blood (2014) 124 (21): 963.

https://doi.org/10.1182/blood.V124.21.963.963

Published: 2014

Journal Articles

Brentuximab Vedotin Monotherapy and in Combination with Dacarbazine in Frontline Treatment of Hodgkin Lymphoma in Patients Aged 60 Years and Above: Interim Results of a Phase 2 Study

Andres Forero-Torres, MD, Beata Holkova, MD, Jeff P. Sharman, MD, Jonathan W. Friedberg, MD, Maurice J. Berkowitz, MD, William Fintel, MD, Robert Chen, MD, Ralph V. Boccia, MD, Mansoor Saleh, MD, Neil Josephson, MD, Maria Corinna Palanca-Wessels, MD PhD, Christopher A. Yasenchak, MD

Blood (2014) 124 (21): 294.

https://doi.org/10.1182/blood.V124.21.294.294

Published: 2014

Journal Articles

Downregulation of CD30, Resistance to MMAE, and Upregulation of MDR1 Are All Associated with Resistance to Brentuximab Vedotin

Robert Chen, MD, Jessie Hou, Edward Newman, PhD, Young Kim, MD, Cecile Donohue, BA, Stephen J. Forman, Susan Kane

Blood (2014) 124 (21): 3643.

https://doi.org/10.1182/blood.V124.21.3643.3643

Published: 2014

Journal Articles

A First-In-Human Phase 1 Study Of The Antibody-Drug Conjugate SGN-CD19A In Relapsed Or Refractory B-Lineage Acute Leukemia and Highly Aggressive Lymphoma

Uma Borate, MD, Amir T. Fathi, MD, Bijal D. Shah, MD, Daniel J. DeAngelo, MD, Ph.D, Lewis B. Silverman, MD, Todd Michael Cooper, Tina M. Albertson, MD, PhD, Megan M. O'Meara, MD, Larissa Sandalic, MS, Faith Stevison, MS, Robert Chen, MD

Blood (2013) 122 (21): 1437.

https://doi.org/10.1182/blood.V122.21.1437.1437

Published: 2013

Journal Articles

Brentuximab Vedotin Administered Before, During, and After Multi-Agent Chemotherapy In Patients (pts) With Newly-Diagnosed CD30+ Mature T- and NK-Cell Lymphomas

Michelle A. Fanale, MD, Steven M. Horwitz, MD, Andres Forero-Torres, MD, Nancy L. Bartlett, MD, Ranjana H. Advani, MD, Barbara Pro, MD, Robert Chen, MD, Andrew Davies, BM PhD, Tim Illidge, PhD, Dirk Huebner, MD, Dana A. Kennedy, PharmD, Andrei R. Shustov, MD

Blood (2013) 122 (21): 4386.

https://doi.org/10.1182/blood.V122.21.4386.4386

Published: 2013

Journal Articles

A Phase 2 Study Of Single-Agent Brentuximab Vedotin For Front-Line Therapy Of Hodgkin Lymphoma In Patients Age 60 Years and Above: Interim Results

Christopher A. Yasenchak, MD, Robert Chen, MD, Jeff P. Sharman, MD, Ralph V. Boccia, MD, Beata Holkova, MD, Peter J. Rosen, MD, Jonathan W. Friedberg, MD, Megan M. O'Meara, MD, Andres Forero-Torres, MD

Blood (2013) 122 (21): 4389.

https://doi.org/10.1182/blood.V122.21.4389.4389

Published: 2013

Journal Articles

Final Results Of A Phase 2 Study Of Vorinostat Plus Rituximab In Newly Diagnosed, Relapsed Or Refractory Indolent Non-Hodgkin's Lymphoma

Robert Chen, MD, Paul Frankel, PhD, Leslie Popplewell, MD, Tanya Siddiqi, MD, Wei Ye, Joel Conrad, BS, Michelle Mott, RN, Auayporn Nademanee, MD, Myo Htut, MD, Stephen J. Forman, MD, Mark Kirschbaum, MD

Blood (2013) 122 (21): 4398.

https://doi.org/10.1182/blood.V122.21.4398.4398

Published: 2013

Journal Articles

Brentuximab Vedotin Improves HCT-CI, CR Status, and Peri-Transplant Toxicity In Patients With Relapsed/Refractory Hodgkin Lymphoma Heading To RIC Allo-HCT

Robert Chen, MD, Joycelynne Palmer, PhD, Ni-Chun Tsai, MS MPH, Sandra H. Thomas, PhD, Tanya Paris, Leslie Popplewell, MD, Chatchada Karanes, MD, Tanya Siddiqi, MD, Auayporn Nademanee, MD, Ji-Lian Cai, MD, Stephen J. Forman, MD

Blood (2013) 122 (21): 3374.

https://doi.org/10.1182/blood.V122.21.3374.3374

Published: 2013

Journal Articles

Immunologic and Clinical Responses To a CD20-Targeted Immunocytokine, DI-Leu16-IL2, In Relapsed Non-Hodgkin Lymphoma

Ryotaro Nakamura, Robert Chen, MD, Joycelynne Palmer, PhD, Karl Gaal, MD, Auayporn Nademanee, MD, Leslie Popplewell, MD, James E. Talmadge, PhD, Stephen Gillies, PhD, David Colcher, PhD, Stephen J. Forman, MD, Andrew Raubitschek, MD

Blood (2013) 122 (21): 1808.

https://doi.org/10.1182/blood.V122.21.1808.1808

Published: 2013

Journal Articles

Three-Year Follow-Up Data and Characterization Of Long-Term Remissions From An Ongoing Phase 2 Study Of Brentuximab Vedotin In Patients With Relapsed Or Refractory Hodgkin Lymphoma

Ajay K. Gopal, MD, Robert Chen, MD, Scott E. Smith, MD, PhD, Stephen M Ansell, M.D.Ph.D., Joseph D Rosenblatt, MD, Kerry J. Savage, MD, MSc, Joseph M. Connors, MD, Andreas Engert, MD, Emily K. Larsen, MS, Dirk Huebner, MD, Eric L. Sievers, MD, Anas Younes, MD

Blood (2013) 122 (21): 4382.

https://doi.org/10.1182/blood.V122.21.4382.4382

Published: 2013

Journal Articles

Selection For Brentuximab Vedotin Resistant Lymphoma Cell Lines Leads To Downregulation Of Surface CD30 Expression

Robert Chen, MD, Jessie Hou, Megan Reddy, Edward Newman, Stephen J. Forman, MD, Susan Kane

Blood (2013) 122 (21): 1280.

https://doi.org/10.1182/blood.V122.21.1280.1280

Published: 2013

Journal Articles

A Retrospective Analysis of Using Pre-Transplant Functional FDG-PET to Predict for Relapse and Survival in Relapsed Hodgkin Lymphoma (HL) Patients Undergoing Autologous Hematopoietic Cell Transplantation (AHCT).

Robert Chen, MD, Joycelynne Palmer, PHD, Leslie Popplewell, MD, Ni-Chun Tsai, MS, Amrita Krishnan, MD, FACP, Margaret O'Donnell, MD, Ryotaro Nakamura, MD, Eileen Smith, MD, Stephen J Forman, MD, Auayporn P. Nademanee, MD

Blood (2009) 114 (22): 1225.

https://doi.org/10.1182/blood.V114.22.1225.1225

Published: 2009

Journal Articles

Allogeneic Hematopoietic Cell Transplantation (allo-HCT) Can Induce Durable Remission in Heavily Pretreated Relapsed Hodgkin Lymphoma. (HL).

Robert Chen, MD, Joycelynne Palmer, PHD, Leslie Popplewell, MD, Jessica Shen, MS, Eileen Smith, MD, Maria Delioukina, MD, Neil Kogut, MD, Joseph Rosenthal, MD, Stephen J Forman, MD, Auayporn P. Nademanee, MD

Blood (2009) 114 (22): 1192.

https://doi.org/10.1182/blood.V114.22.1192.1192

Published: 2009

Journal Articles

Phase I Study of Bortezomib in Combination with Gemcitabine in Relapsed/Refractory Intermediate Grade B-Cell and Mantle Cell Non-Hodgkin's Lymphoma.

Mark Kirschbaum, MD, Maria Delioukina, Leslie Popplewell, MD, David S. Snyder, MD, Pablo Parker, Robert Chen, MD, Jasmine Zain, MD, Deron Matsuoka, Nony Obadike, Paul Frankel, Auayporn P. Nademanee, MD, Stephen J Forman, MD

Blood (2009) 114 (22): 1682.

https://doi.org/10.1182/blood.V114.22.1682.1682

Published: 2009

Journal Articles

Successful Orthotopic Liver Transplantation in Severe Hemophilia A with High Responding Inhibitor.

Robert Chen, MD, Seligman Paul, MD, Justin Call, MD, Brenda Riske, RN, Ruth Ann Kirschman, RN, Sue Geraghty, RN, Stabler Sally, MD

Blood (2007) 110 (11): 3968.

https://doi.org/10.1182/blood.V110.11.3968.3968

Published: 2007

Journal Articles

B-Type Natriuretic Peptide (BNP) and Mitral Velocity E/A Ratio (MV E/A) Are Two Important Noninvasive Functional Indices of Cardiac AL Amyloidosis.

Peter Kabos, MD, Qaiser Bashir, MD, Robert Chen, MD, JoAnn Lindenfeld, MD, Han Myint, MD, Choon Kee Lee, MD

Blood (2007) 110 (11): 4773.

https://doi.org/10.1182/blood.V110.11.4773.4773

Published: 2007

NARROW

Ibrutinib Plus Venetoclax in Patients With Relapsed/Refractory Mantle Cell Lymphoma: Results From the Safety Run-In Period of the Phase 3 Sympatico Study

Consolidation with Nivolumab and Brentuximab Vedotin after Autologous Hematopoietic Cell Transplantation in Patients with High-Risk Hodgkin Lymphoma

Phase 1/2 Study of AUTO3 the First Bicistronic Chimeric Antigen Receptor (CAR) Targeting CD19 and CD22 Followed By an Anti-PD1 in Patients with Relapsed/Refractory (r/r) Diffuse Large B Cell Lymphoma (DLBCL): Results of Cohort 1 and 2 of the Alexander Study

Ibrutinib Therapy in Patients with Relapsed/Refractory Marginal Zone Lymphoma: Analysis By Prior Rituximab Treatment and Baseline Mutations

Interim Analysis of a Phase 1 Study of the Antibody-Drug Conjugate SGN-CD19A in Relapsed or Refractory B-Lineage Acute Leukemia and Highly Aggressive Lymphoma

Brentuximab Vedotin Monotherapy and in Combination with Dacarbazine in Frontline Treatment of Hodgkin Lymphoma in Patients Aged 60 Years and Above: Interim Results of a Phase 2 Study

Downregulation of CD30, Resistance to MMAE, and Upregulation of MDR1 Are All Associated with Resistance to Brentuximab Vedotin

A First-In-Human Phase 1 Study Of The Antibody-Drug Conjugate SGN-CD19A In Relapsed Or Refractory B-Lineage Acute Leukemia and Highly Aggressive Lymphoma

Brentuximab Vedotin Administered Before, During, and After Multi-Agent Chemotherapy In Patients (pts) With Newly-Diagnosed CD30+ Mature T- and NK-Cell Lymphomas

A Phase 2 Study Of Single-Agent Brentuximab Vedotin For Front-Line Therapy Of Hodgkin Lymphoma In Patients Age 60 Years and Above: Interim Results

Final Results Of A Phase 2 Study Of Vorinostat Plus Rituximab In Newly Diagnosed, Relapsed Or Refractory Indolent Non-Hodgkin's Lymphoma

Brentuximab Vedotin Improves HCT-CI, CR Status, and Peri-Transplant Toxicity In Patients With Relapsed/Refractory Hodgkin Lymphoma Heading To RIC Allo-HCT

Immunologic and Clinical Responses To a CD20-Targeted Immunocytokine, DI-Leu16-IL2, In Relapsed Non-Hodgkin Lymphoma

Three-Year Follow-Up Data and Characterization Of Long-Term Remissions From An Ongoing Phase 2 Study Of Brentuximab Vedotin In Patients With Relapsed Or Refractory Hodgkin Lymphoma

Selection For Brentuximab Vedotin Resistant Lymphoma Cell Lines Leads To Downregulation Of Surface CD30 Expression

A Retrospective Analysis of Using Pre-Transplant Functional FDG-PET to Predict for Relapse and Survival in Relapsed Hodgkin Lymphoma (HL) Patients Undergoing Autologous Hematopoietic Cell Transplantation (AHCT).

Allogeneic Hematopoietic Cell Transplantation (allo-HCT) Can Induce Durable Remission in Heavily Pretreated Relapsed Hodgkin Lymphoma. (HL).

Phase I Study of Bortezomib in Combination with Gemcitabine in Relapsed/Refractory Intermediate Grade B-Cell and Mantle Cell Non-Hodgkin's Lymphoma.

Successful Orthotopic Liver Transplantation in Severe Hemophilia A with High Responding Inhibitor.

B-Type Natriuretic Peptide (BNP) and Mitral Velocity E/A Ratio (MV E/A) Are Two Important Noninvasive Functional Indices of Cardiac AL Amyloidosis.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only